

## PRESS RELEASE

### COMMERCIALIZATION OF ORALAIR IN THE US: POSSIBLE COOPERATION WITH GREER LABORATORIES, INC.

**Antony, France, 8 March 2013** – Stallergenes S.A. (Euronext Paris CAC small) plans to evaluate possible cooperation with Greer Laboratories, Inc. for the US distribution of Oralair, its 5-grass pollen extract allergen immunotherapy (AIT) sublingual tablet. Stallergenes will judge this opportunity on its own merit, regardless of Ares Life Sciences' announcement of the signing of a definitive agreement to acquire Greer Laboratories, Inc..

On 18 February 2013, Stallergenes announced that the FDA had agreed to review its Biologics License Application (BLA) for Oralair.

#### ABOUT STALLERGENES

Stallergenes is an international biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatment, Stallergenes devotes around 20% of its annual gross sales to Research & Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2012, the company generated sales of €240 million, and more than 500,000 patients were treated with Stallergenes products.

Euronext Paris (Compartment B)  
CAC small  
ISIN: FR0000065674  
Reuters: GEN.PA  
Bloomberg: GEN.FP



Additional information is available at <http://www.stallergenes.com>

#### *Forward-looking statements related to Stallergenes*

*This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.*

**Contacts:**

Roberto Gradnik, Chief Executive Officer  
Tel. +33 1 55 59 20 04

**Investor and analyst relations**

Christian Thiry  
Chief Financial Officer  
Tel. +33 1 55 59 20 95  
e-mail: investorrelations@stallergenes.com

**Press Relations**

Lise Lemonnier  
Senior Communication & Public Affairs Director  
Tel. + 33 1 55 59 20 96  
e-mail: llemonnier@stallergenes.com

**Investor and press relations agency:**

FTI Consulting – Press contact  
Emmanuelle Flobert  
Tel. +33 1 47 03 68 56  
emmanuelle.flobert@fticonsulting.com

FTI Consulting – Analyst and investor contact  
Stéphanie Bia  
Tel. +33 1 47 03 68 16  
stephanie.bia@fticonsulting.com